This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Plaintiffs bringing US antitrust claims against Boehringer say QVAR decision against Teva supports their case

( November 8, 2024, 20:25 GMT | Official Statement) -- MLex Summary: Plaintiffs bringing US antitrust claims against Boehringer Ingelheim Pharmaceuticals for allegedly manipulating the US Food and Drug Administration’s patent listing process to unlawfully thwart generic competition in multiple markets told a federal judge that a recent decision against Teva Pharmaceuticals supports their claims. They opposed dismissal, saying that the decision against Teva held that “plausible allegations based on some reasons other than a given patent’s invalidity at the pleading stage was not fatal and merely ‘raise a disputed issue of fact'.” See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections